<p>BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company
Main scenario: consider long positions from corrections above the level of 1.2046 with a target of 1.2465 – 1.2598. Alternative scenario: breakout and consolidation below the level of 1.2046 will allo
Leave a Comment